Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)

As gov­ern­ment fund­ing dries up, Pfiz­er ex­pects to charge pri­vate pay­ers $110+ for Covid-19 vac­cine

For months, com­pa­nies be­hind Covid-19 vac­cines and ther­a­pies have been talk­ing about tran­si­tion­ing to a pri­vate com­mer­cial mar­ket once the gov­ern­ment fund­ing dries up. As its pur­chase pro­gram with the US comes to an end, Pfiz­er is putting a dol­lar fig­ure to the dis­cus­sion.

Pfiz­er plans to charge $110 to $130 for its BioN­Tech-part­nered Covid-19 shot, al­most qua­dru­pling the price, An­gela Lukin, glob­al pri­ma­ry care & US pres­i­dent, told Reuters and Wall Street Jour­nal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.